Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | RECQL | P46063 | 1/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | NPC1 | O15118 | 3/20 | 0.67 |
| ▸ | RAB9A | P51151 | 3/20 | 0.67 |
| ▸ | HTT | P42858 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17050825 | 0.86 | ALDH1A1 (0.74) | TSHRALDH1A1RECQLPOLBNPC1 | |
| SCHEMBL8401361 | 0.86 | MAPT (0.69) | TSHRRECQLPOLBNPC1RAB9A | |
| SCHEMBL18381424 | 0.84 | TSHR (0.76) | TSHRALDH1A1RECQLPOLBGAA | |
| SCHEMBL16133680 | 0.83 | ALDH1A1 (1.00) | TSHRALDH1A1RECQLPOLBGAA | |
| SCHEMBL3539326 | 0.80 | ALDH1A1 (0.72) | TSHRALDH1A1RECQLPOLBGAA | |
| SCHEMBL13406090 | 0.79 | TSHR (0.62) | TSHRALDH1A1RECQLNPC1RAB9A | |
| SCHEMBL19265679 | 0.78 | ALDH1A1 (0.62) | TSHRALDH1A1RECQLPOLBNPC1 | |
| SCHEMBL20715450 | 0.78 | POLB (0.83) | POLBRAB9AHTTGAATP53 | |
| SCHEMBL13406088 | 0.78 | TSHR (0.60) | TSHRALDH1A1RECQLNPC1RAB9A | |
| SCHEMBL16768668 | 0.77 | ALDH1A1 (0.73) | TSHRALDH1A1RECQLNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9776996-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20160326170-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2016-11-10 | — | — | US | disclosed |
| US-20160024081-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | Epizyme, Inc. | 2016-01-28 | — | — | US | disclosed |
| US-9045477-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2015-06-02 | — | — | US | disclosed |
| US-20140296283-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | Epizyme, Inc. (US) | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024081-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | CYP3A5, PAICS, CYP4B1 | TSHR 4516/4885ALDH1A1 594/4885RECQL 870/4885 |
| US-20140296283-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | CYP3A5, PAICS, CYP4B1 | TSHR 4516/4885ALDH1A1 594/4885RECQL 870/4885 |
| US-20160326170-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | CYP3A5, PAICS, CYP4B1 | TSHR 4516/4885ALDH1A1 594/4885RECQL 870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.